Clinical evidence

Find out more about the evidence that supports the use of TAVI to treat patients with severe aortic stenosis (sAS).1-8 TAVI has been shown to benefit a wide range of sAS patients, including those with differing levels of surgical risk, patients with the typical comorbidities and risk factors associated with sAS.6-11

TAVI Trials

Discover more about the trials that have demonstrated comparable or better outcomes with TAVI compared with surgery (sAVR) in sAS patients with low, intermediate or high surgical risk. In addition, see the trial of TAVI versus standard treatment in patients with inoperable aortic stenosis.1-8
Valve-in-valve-TAVI-procedures
Active-patient-post-TAVI-procedure

Quality of life

At 1 month post-intervention, health status was significantly better in patients who underwent TAVI compared to those who underwent sAVR.  TAVI was also associated with health status benefits at 12 months compared with sAVR in low surgical risk patients.12-14

Patient conditions and special risks

Many patients have multiple co-morbidities, which can make treatment decisions less clear. The following page provides valuable insights on how to manage these clinically challenging patients.

Coming soon
TAVI-patient

Patient conditions and special risks

Many patients have multiple co-morbidities, which can make treatment decisions less clear. The following page provides valuable insights on how to manage these clinically challenging patients.

Coming soon
TAVI-patient
Rectangle-39

Healthcare system impact

Examine the data that show TAVI has a number of benefits for healthcare systems. This includes low complication rates,9 shorter procedure time,10 faster recovery,12 and reduced length of hospital stays.3,5

TAVI valve durability

Valve durability is a key consideration for intervention choice. Assess the follow-up data from the PARTNER Trials, which demonstrate the durability of SAPIEN 3 valves used in TAVI.6
SAPIEN-3-aortic-valve-replacement

Stay informed with our newsletter

Our monthly updates provide you the latest developments in TAVI and aortic stenosis.     Read more

References

  • 1Leon MB, Smith CR, Mack M, et al. N Engl J Med 2010; 363:1597-1607.
  • 2Smith CR, Leon MB, Mack MJ, et al. N Engl J Med 2011;364:2187-2198.
  • 3Leon MB, Smith CR, Mack MJ, et al. N Engl J Med 2016;374:1609-1620.
  • 4Kapadia SR, Leon MB, Makkar RR, et al. Lancet 2015;385:2485-2491.
  • 5Thourani VH, Kodali S, Makkar RR, et al. Lancet 2016;387:2218-2225.
  • 6Mack MJ, Leon MB, Smith CR, et al. Lancet 2015;385:2477-2484.
  • 7Webb JG, Doshi D, Mack MJ, et al. JACC Cardiovasc Interv 2015;8:1797-1806.
  • 8Mack MJ et al. N Engl J Med. 2019;380(18):1695-1705.
  • 9Tamburino C, Barbanti M, Capodanno D et al. Am J Cardiol 2012;109:1487–1493.
  • 10Hamm CW, Möllmann H, Holzhey D et al. Eur Heart J 2014;35:1588–1598.
  • 11Kleczyński, P, Bagieński M, Sorysz D, et al. Kardiol Pol 2014;72:612–616.
  • 12Baron SJ, Magnuson EA, Lu M, et al. J Am Coll Cardiol 2019;74(23):2833-2842.
  • 13Baron SJ, Arnold SV, Wang K, et al. JAMA Cardiol 2017;2:837-845.
  • 14Reynolds MR, Magnuson EA, Wang K, et al. J Am Coll Cardiol 2012;60:548-558.

Content relating to Tavi.today is intended for healthcare professionals. Click OK to confirm you are a healthcare professional and proceed.

Skip to content